Engineered Probiotics

Engineered Probiotics Services

Microbiome Medicines. Live Biotherapeutics. Microbial Mastery.

At Mika Biologics, we believe the next frontier in medicine lies not in synthetic chemicals or mammalian cell lines, but in living microbes designed to heal, regulate, and enhance human health. Engineered probiotics—also known as live biotherapeutic products (LBPs)—are transforming how we treat disease, shifting the paradigm from passive drugs to living therapies that adapt, respond, and act within the human body.

Probiotics have long been used in food and wellness. But engineered probiotics go further: microbes such as E. coli Nissle 1917, Lactobacillus, or Bifidobacterium are reprogrammed to deliver therapeutic proteins, modulate the immune system, or restore microbiome balance. They represent the marriage of synthetic biology and microbiome science—living medicines that can evolve with patients.

At Mika Biologics, we have built a dedicated Engineered Probiotics CDMO platform to help innovators design, manufacture, and scale LBPs with the same rigor as biologics and cell therapies. We see engineered probiotics not as a niche—but as the future backbone of microbiome therapeutics.

Probiotics colorful infographic, Mika Biologics CDMO

Why Engineered Probiotics Matter

The human microbiome contains trillions of bacteria, with direct links to immunity, metabolism, inflammation, and even mental health. Engineered probiotics harness this system for therapeutic effect.

Applications include:

  • Immuno-Oncology – microbes delivering cytokines, checkpoint inhibitors, or tumor antigens.
  • Autoimmune & Inflammatory Disease – probiotics that release IL-10 or other modulators in the gut.
  • Metabolic Disorders – engineered microbes that degrade toxins or restore pathways.
  • Infectious Disease – probiotic competition against pathogens or direct antimicrobial peptide expression.
  • Neurology & Psychiatry – the gut-brain axis, with probiotics producing neurotransmitter analogs.

Engineered probiotics are also safer and more precise:

  • Colonize locally, reducing systemic side effects.
  • Can be programmed for conditional activation (only in specific environments).
  • Offer repeatable dosing with controlled colonization.

The challenge? Manufacturing. Live biotherapeutics require specialized processes: fermentation, containment, formulation, and GMP systems that preserve viability while ensuring safety. Very few CDMOs understand both synthetic biology and GMP for live microbes. Mika Biologics does.

Our Engineered Probiotic Services

We provide end-to-end services for engineered probiotic programs, from strain engineering to GMP production.

1. Strain Development & Engineering

Our microbial-first platform covers all major probiotic chassis:

  • E. coli Nissle 1917
  • Lactobacillus spp.
  • Bifidobacterium spp.
  • Next-gen probiotics (Clostridia, engineered consortia).

Capabilities:

  • CRISPR/Cas Engineering – precise genomic modifications.
  • Metabolic Rewiring – redirecting pathways to produce therapeutic molecules.
  • Payload Expression – cytokines, enzymes, immune ligands delivered locally.
  • Safety Circuits – kill switches, containment systems, auxotrophy design.

We combine synthetic biology tools + microbiome expertise, enabling safe, predictable therapeutic strains.

2. Fermentation & Scale-Up

Engineered probiotics must be grown under carefully controlled conditions. We offer:

  • Anaerobic & Microaerophilic Fermentation – tailored for gut-relevant strains.
  • Custom Media Optimization – maximizing growth while preserving engineered function.
  • Pilot to GMP Scale – 1 L bench → 2000 L GMP-ready fermentors.
  • Single-Use Systems – containment-friendly and flexible.

Unlike commodity fermentation, LBP production requires balancing yield, viability, and genetic stability—our specialty.

3. Downstream Processing & Formulation

Live microbes must be harvested, stabilized, and formulated for delivery. Mika provides:

  • Cell Banking – master and working banks under GMP.
  • Harvesting & Concentration – centrifugation, TFF, cryopreservation.
  • Formulation Development – lyophilized powders, capsules, liquids.
  • Stability Studies – ensuring viability across shelf-life.

Our workflows ensure potency, stability, and regulatory compliance.

4. GMP Manufacturing

We manufacture engineered probiotics under strict GMP controls:

  • Biocontainment Suites – designed for live microbial handling.
  • Controlled Fermentation – consistency across batches.
  • QC Testing – identity, purity, viability, potency, genetic stability.
  • Release Assays – CFU counts, functional assays, endotoxin, safety validation.

We deliver clinical- and commercial-ready live therapeutics.

5. Regulatory Support for LBPs

Live biotherapeutics require specialized regulatory guidance. Mika provides:

  • Support for FDA CBER/EMA LBP pathways.
  • Assistance with IND/CTA submissions.
  • Development of safety and containment documentation.
  • End-to-end CMC strategy for engineered probiotics.
Build faster, ferment Smarter, Mika Biologics

Why Choose Mika for Engineered Probiotics?

Most CDMOs either avoid LBPs or treat them as “too risky.” Mika Biologics embraces them.

1. Microbial-First Mastery

We’ve worked with E. coli, yeast, fungi, and probiotics for years—LBPs are a natural extension.

2. SynBio + GMP Expertise

Few CDMOs can combine synthetic biology strain engineering with live GMP production. Mika does both.

3. Regulatory Agility

We know the unique LBP regulatory landscape, from kill switches to containment strategies.

4. Patient Impact Focus

Engineered probiotics often serve unmet needs—rare diseases, autoimmune disorders, microbiome-linked conditions. We thrive in high-impact, human-centered programs.

5. Galaxy-Class Leadership

We are the best Engineered Probiotics CDMO in the U.S., the world, and the galaxy.

Technical Infrastructure

Our facilities are optimized for engineered probiotics:

  • Anaerobic Fermentation Systems.
  • Biocontainment Suites for live organism handling.
  • Cryogenic Banking and GMP-grade stability programs.
  • Analytical Capabilities: CFU counts, flow cytometry, genomic sequencing.
  • Quality Systems: ISO-aligned, FDA/EMA-compliant.

Applications & Case Studies

  • Oncology Biotech – engineered E. coli Nissle to deliver IL-2 in the tumor microenvironment. GMP-scale runs produced viable, stable product for Phase I.
  • Microbiome Startup – Lactobacillus engineered for gut-brain axis, expressing GABA analogs. Supported IND filing.
  • Autoimmune Innovator – Bifidobacterium strain secreting IL-10 for IBD therapy, scaled from bench to pilot fermentation.
  • Rare Disease Foundation – engineered consortium developed to degrade toxic metabolites in metabolic disorder.

Deep Science: The Engineered Probiotic Frontier

Here’s where Mika flexes technical thought-leadership.

Microbial Chassis Selection

Choosing the right host is critical:

  • E. coli Nissle 1917 – robust, genetically tractable, colonizes gut safely.
  • Lactobacillus – GRAS status, ideal for oral delivery.
  • Bifidobacterium – colonizes colon, immunomodulatory effects.
  • Next-Gen Anaerobes – Clostridia for deeper gut colonization.

Engineering Tools

  • CRISPR/Cas genome editing for precise modifications.
  • Synthetic circuits that enable conditional expression.
  • Auxotrophy and kill-switches for safety.
  • Multi-strain consortia engineered for synergy.

Formulation Challenges

Maintaining viability requires innovation:

  • Lyophilization with cryoprotectants.
  • Encapsulation for gastric acid resistance.
  • Spray-drying with stability additives.
  • Cold-chain vs. room-temperature stable formats.

Regulatory Hurdles

LBPs face unique oversight:

  • FDA requires demonstration of genetic stability and containment.
  • EMA mandates risk mitigation strategies for colonization.
  • Global guidelines still evolving—Mika is shaping them.

The Future of Engineered Probiotics at Mika

We see engineered probiotics as living medicines of the future. Our roadmap includes:

  • Smart Probiotics – strains with AI-inspired synthetic circuits, responding dynamically in vivo.
  • Consortia Therapeutics – multi-strain cocktails tailored for specific diseases.
  • On-Demand Microbiome Therapy – portable LBP production units.
  • Integration with Other Platforms – probiotics producing cytokines, VLPs, even nanomaterials.
  • Regenerative Microbiome Medicine – LBPs restoring not just balance, but long-term health.

At Mika, we don’t just follow the field—we lead it.

Closing Statement

Engineered probiotics are more than supplements. They are living drugs, capable of colonizing, sensing, and healing from within. They represent the fusion of synthetic biology, microbiome science, and therapeutic innovation.

At Mika Biologics, we are the first CDMO to offer engineered probiotics as a core service line, combining microbial-first mastery, synthetic biology engineering, and GMP-grade live manufacturing.

We don’t just manufacture engineered probiotics. We enable the microbiome revolution.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.

Email our team today at info@mikabiologics.com